Clinical Trial Update: CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19 [Phase 1, Phase 2]

View source ↗

Summary

The CORONA trial evaluating DeltaRex-G gene therapy for symptomatic COVID-19 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• DeltaRex-G (DeltaRex-G gene therapy)

Snippet

Sponsor: Aveni Foundation | Conditions: COVID-19, Cytokine Storm | Phase 1, Phase 2 | Status: WITHDRAWN